{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T09:59:22Z","timestamp":1705658362434},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Molecular Partners AG, 8952 Z\u00fcrich-Schlieren, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical studies have proven antiviral effectiveness of treatment with a Designed Ankyrin Repeat Protein (DARPin) specific against the spike protein of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). More information on transport mechanisms and efficiency to the site of action is desirable. Transepithelial migration through air\u2013liquid interface (ALI) cultures of reconstituted human bronchial epithelia (HBE) was assessed by Enzyme-Linked Immunosorbent Assays and Confocal Laser Scanning Microscopy for different DARPin designs in comparison to a monoclonal antibody. Antiviral efficacy against authentic SARS-CoV-2, applied apically on HBE, was investigated based on viral titers and genome equivalents, after administration of therapeutic candidates on the basal side. Transepithelial translocation of all DARPin candidates and the monoclonal antibody was efficient and dose dependent. Small DARPins and the antibody migrated more efficiently than larger molecules, indicating different transport mechanisms involved. \nMicroscopic analyses support this, demonstrating passive paracellular transport of smaller DARPins and transcellular migration of the larger molecules. All therapeutic candidates applied to the basal side of HBE conferred effective protection against SARS-CoV-2 infection. In summary, we have shown that DARPins specific against SARS-CoV-2 translocate across intact airway epithelia and confer effective protection against infection and viral replication.<\/jats:p>","DOI":"10.1038\/s41598-023-32269-1","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:40:39Z","timestamp":1680741639000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transport of Designed Ankyrin Repeat Proteins through reconstituted human bronchial epithelia and protection against SARS-CoV-2"],"prefix":"10.1038","volume":"13","author":[{"given":"Lisa","family":"K\u00fcnzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ryter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaira","family":"Leni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Baumlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Salathe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Walser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Engler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Geiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"32269_CR1","unstructured":"WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int."},{"key":"32269_CR2","unstructured":"Ritchie, H. et al. Coronavirus Pandemic (COVID-19). Coronavirus (COVID-19) Vaccinations https:\/\/ourworldindata.org\/covid-vaccinations (2020)."},{"key":"32269_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","volume":"386","author":"V Hall","year":"2022","unstructured":"Hall, V. et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N. Engl. J. Med. 386, 1207\u20131220 (2022).","journal-title":"N. Engl. J. Med."},{"key":"32269_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01382-3","author":"S Rothenberger","year":"2022","unstructured":"Rothenberger, S. et al. The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-022-01382-3 (2022).","journal-title":"Nat. Biotechnol."},{"key":"32269_CR5","unstructured":"Novartis. Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19. https:\/\/www.novartis.com\/news\/media-releases\/novartis-and-molecular-partners-announce-start-empathy-clinical-trial-ensovibep-treatment-covid-19 (2021)."},{"key":"32269_CR6","unstructured":"ACTIV-3\/TICO Bamlanivimab Study Group et al. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels: A Randomized Controlled Trial. Ann. Intern. Med. 175, 234\u2013243 (2022)."},{"key":"32269_CR7","unstructured":"ACTIV-3\/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis. 22, 622\u2013635 (2022)."},{"key":"32269_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S2213-2600(22)00215-6","volume":"10","author":"TL Holland","year":"2022","unstructured":"Holland, T. L. et al. Tixagevimab\u2013cilgavimab for treatment of patients hospitalised with COVID-19: A randomised, double-blind, phase 3 trial. Lancet Respir. Med. 10, 972\u2013984 (2022).","journal-title":"Lancet Respir. Med."},{"key":"32269_CR9","doi-asserted-by":"crossref","unstructured":"ACTIV-3\/TICO Study Group et al. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19\u202f: A Randomized Controlled Trial. Ann. Intern. Med. 175, 1266\u20131274 (2022).","DOI":"10.7326\/M22-1503"},{"key":"32269_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","volume":"55","author":"A Pl\u00fcckthun","year":"2015","unstructured":"Pl\u00fcckthun, A. Designed Ankyrin Repeat Proteins (DARPins): Binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 55, 489\u2013511 (2015).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"32269_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/protein\/gzx022","volume":"30","author":"D Steiner","year":"2017","unstructured":"Steiner, D. et al. Half-life extension using serum albumin-binding DARPin\u00ae domains. Protein Eng. Des. Sel. 30, 583\u2013591 (2017).","journal-title":"Protein Eng. Des. Sel."},{"key":"32269_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00682","author":"KM Knudsen Sand","year":"2015","unstructured":"Knudsen Sand, K. M. et al. Unraveling the interaction between FcRn and albumin: Opportunities for design of albumin-based therapeutics. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2014.00682 (2015).","journal-title":"Front. Immunol."},{"key":"32269_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/0962-8924(92)90036-M","volume":"2","author":"J-P Kraehenbuhl","year":"1992","unstructured":"Kraehenbuhl, J.-P. & Neutra, M. R. Transepithelial transport and mucosal defence II: Secretion of IgA. Trends Cell Biol. 2, 170\u2013174 (1992).","journal-title":"Trends Cell Biol."},{"key":"32269_CR14","doi-asserted-by":"publisher","first-page":"55S","DOI":"10.1378\/chest.101.3_Supplement.55S","volume":"101","author":"JE Casanova","year":"1992","unstructured":"Casanova, J. E. Transepithelial transport of macromolecules. CHEST 101, 55S-58S (1992).","journal-title":"CHEST"},{"key":"32269_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.25.256339","author":"M Walser","year":"2021","unstructured":"Walser, M. et al. Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates. Biorxiv https:\/\/doi.org\/10.1101\/2020.08.25.256339 (2021).","journal-title":"Biorxiv"},{"key":"32269_CR16","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1158\/0008-5472.CAN-09-2724","volume":"70","author":"C Zahnd","year":"2010","unstructured":"Zahnd, C. et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: Effects of affinity and molecular size. Cancer Res. 70, 1595\u20131605 (2010).","journal-title":"Cancer Res."},{"key":"32269_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature07255","volume":"455","author":"W He","year":"2008","unstructured":"He, W. et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature 455, 542\u2013546 (2008).","journal-title":"Nature"},{"key":"32269_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.20020400","volume":"196","author":"GM Spiekermann","year":"2002","unstructured":"Spiekermann, G. M. et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life\u202f: Functional expression of FcRn in the mammalian lung. J. Exp. Med. 196, 303\u2013310 (2002).","journal-title":"J. Exp. Med."},{"key":"32269_CR19","doi-asserted-by":"publisher","first-page":"L247","DOI":"10.1152\/ajplung.00235.2002","volume":"284","author":"K-J Kim","year":"2003","unstructured":"Kim, K.-J. & Malik, A. B. Protein transport across the lung epithelial barrier. Am. J. Physiol.-Lung Cell. Mol. Physiol. 284, L247\u2013L259 (2003).","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"32269_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0169-409X(95)00113-L","volume":"19","author":"JS Patton","year":"1996","unstructured":"Patton, J. S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19, 3\u201336 (1996).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"32269_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1369\/0022155417705095","volume":"65","author":"S Latvala","year":"2017","unstructured":"Latvala, S., Jacobsen, B., Otteneder, M. B., Herrmann, A. & Kronenberg, S. Distribution of FcRn across species and tissues. J. Histochem. Cytochem. 65, 321\u2013333 (2017).","journal-title":"J. Histochem. Cytochem."},{"key":"32269_CR22","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1128\/AEM.00722-15","volume":"81","author":"KE Kram","year":"2015","unstructured":"Kram, K. E. & Finkel, S. E. Rich medium composition affects escherichia coli survival, glycation, and mutation frequency during long-term batch culture. Appl. Environ. Microbiol. 81, 4442\u20134450 (2015).","journal-title":"Appl. Environ. Microbiol."},{"key":"32269_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.atmosenv.2012.11.055","volume":"68","author":"L K\u00fcnzi","year":"2013","unstructured":"K\u00fcnzi, L. et al. Responses of lung cells to realistic exposure of primary and aged carbonaceous aerosols. Atmos. Environ. 68, 143\u2013150 (2013).","journal-title":"Atmos. Environ."},{"key":"32269_CR24","doi-asserted-by":"publisher","first-page":"11801","DOI":"10.1038\/srep11801","volume":"5","author":"L K\u00fcnzi","year":"2015","unstructured":"K\u00fcnzi, L. et al. Toxicity of aged gasoline exhaust particles to normal and diseased airway epithelia. Sci. Rep. 5, 11801 (2015).","journal-title":"Sci. Rep."},{"key":"32269_CR25","doi-asserted-by":"publisher","first-page":"29998","DOI":"10.1074\/jbc.M110.113621","volume":"285","author":"A Schmid","year":"2010","unstructured":"Schmid, A. et al. Decreased soluble adenylyl cyclase activity in cystic fibrosis is related to defective apical bicarbonate exchange and affects ciliary beat frequency regulation. J. Biol. Chem. 285, 29998\u201330007 (2010).","journal-title":"J. Biol. Chem."},{"key":"32269_CR26","first-page":"183","volume":"107","author":"ML Fulcher","year":"2005","unstructured":"Fulcher, M. L., Gabriel, S., Burns, K. A., Yankaskas, J. R. & Randell, S. H. Well-differentiated human airway epithelial cell cultures. Methods Mol. Med. 107, 183\u2013206 (2005).","journal-title":"Methods Mol. Med."},{"key":"32269_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"32269_CR28","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.10.475377","author":"HR Jonsdottir","year":"2022","unstructured":"Jonsdottir, H. R. et al. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. Biomed. Pharmcother. https:\/\/doi.org\/10.1101\/2022.01.10.475377 (2022).","journal-title":"Biomed. Pharmcother."},{"key":"32269_CR29","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. 117, 7001\u20137003 (2020).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"32269_CR30","doi-asserted-by":"publisher","first-page":"e0215822","DOI":"10.1371\/journal.pone.0215822","volume":"14","author":"N Nao","year":"2019","unstructured":"Nao, N. et al. Consensus and variations in cell line specificity among human metapneumovirus strains. PLoS ONE 14, e0215822 (2019).","journal-title":"PLoS ONE"},{"key":"32269_CR31","first-page":"227","volume":"2","author":"C Spearman","year":"1908","unstructured":"Spearman, C. The method of right and wrong cases (Constant Stimuli) without Gauss\u2019s formulae. Br. J. Psychol. 2, 227\u2013242 (1908).","journal-title":"Br. J. Psychol."},{"key":"32269_CR32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF01863914","volume":"162","author":"G K\u00e4rber","year":"1931","unstructured":"K\u00e4rber, G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedebergs Arch. F\u00fcr Exp. Pathol. Pharmakol. 162, 480\u2013483 (1931).","journal-title":"Naunyn-Schmiedebergs Arch. F\u00fcr Exp. Pathol. Pharmakol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32269-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32269-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32269-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:42:21Z","timestamp":1680741741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32269-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32269"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32269-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.K, S.R., Z.L., N.B., M.S., O.E. and M.G. declare no competing financial interest. M.W. and A.C. are employees of Molecular Partners and own performance share units and\/or stock of the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5537"}}